1. Home
  2. HFBL vs NXTC Comparison

HFBL vs NXTC Comparison

Compare HFBL & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Home Federal Bancorp Inc. of Louisiana

HFBL

Home Federal Bancorp Inc. of Louisiana

N/A

Current Price

$17.56

Market Cap

41.6M

Sector

Finance

ML Signal

N/A

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$13.52

Market Cap

44.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HFBL
NXTC
Founded
1924
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.6M
44.6M
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
HFBL
NXTC
Price
$17.56
$13.52
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
2.5K
27.3K
Earning Date
04-29-2026
06-08-2026
Dividend Yield
2.90%
N/A
EPS Growth
7.69
N/A
EPS
1.07
N/A
Revenue
$1,303,000.00
$22,378,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.42
N/A
Revenue Growth
17.49
N/A
52 Week Low
$12.32
$0.23
52 Week High
$20.00
$15.74

Technical Indicators

Market Signals
Indicator
HFBL
NXTC
Relative Strength Index (RSI) 41.42 52.39
Support Level $12.87 $10.73
Resistance Level $18.20 $13.47
Average True Range (ATR) 0.19 1.10
MACD -0.21 0.05
Stochastic Oscillator 5.39 64.68

Price Performance

Historical Comparison
HFBL
NXTC

About HFBL Home Federal Bancorp Inc. of Louisiana

Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: